Nyxoah (NYXH) to Release Earnings on Tuesday

Key Points

• Nyxoah (NASDAQ: NYXH) is expected to announce its Q2 2025 earnings on August 5th, with analysts projecting a loss of ($0.60) per share and revenue of $1.33 million.
• In its last earnings report, Nyxoah missed estimates with a loss of ($0.63) per share and revenue of $1.12 million, falling short of the expected $1.64 million.
• Recent analyst activities include Stifel Nicolaus cutting their price target from $15.00 to $14.00 while maintaining a "buy" rating on the stock.

Nyxoah (NASDAQ:NYXH - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $1.33 million for the quarter.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.64 million. Nyxoah had a negative net margin of 1,571.39% and a negative return on equity of 63.37%. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Stock Down 2.1%

Shares of NASDAQ:NYXH traded down $0.16 during mid-day trading on Friday, hitting $7.30. 60,727 shares of the company traded hands, compared to its average volume of 43,328. The stock has a market cap of $248.64 million, a P/E ratio of -3.43 and a beta of 1.61. The company has a current ratio of 3.59, a quick ratio of 3.35 and a debt-to-equity ratio of 0.22. Nyxoah has a 12-month low of $5.55 and a 12-month high of $11.87. The stock has a 50-day moving average price of $7.72 and a two-hundred day moving average price of $8.29.

Analyst Upgrades and Downgrades

NYXH has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Nyxoah in a research report on Tuesday, April 8th. Stifel Nicolaus decreased their price objective on Nyxoah from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, April 21st.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.